LY-3209590 is a fusion protein commercialized by Eli Lilly and Co, with a leading Phase III program in Type 2 Diabetes. According to Globaldata, it is involved in 20 clinical trials, of which 10 were completed, 9 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of LY-3209590’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for LY-3209590 is expected to reach an annual total of $263 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
LY-3209590 (Basal insulin-Fc) is under development for the treatment of type 1 and 2 diabetes. It is administered through subcutaneous route. Basal insulin-Fc is a fusion protein comprises of insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker. It is a new molecular entity (NME).
Eli Lilly and Co Overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$28,541.4 million for the fiscal year ended December 2022 (FY2022), an increase of 0.8% over FY2021. The operating profit of the company was US$7,127.3 million in FY2022, compared to an operating profit of US$5,951.9 million in FY2021. The net profit of the company was US$6,244.8 million in FY2022, compared to a net profit of US$5,581.7 million in FY2021.
For a complete picture of LY-3209590’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.